Algernon Pharmaceuticals Inc
CNSX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Algernon Pharmaceuticals Inc
CNSX:AGN
|
CA |
|
Renaissance United Ltd
SGX:I11
|
SG |
|
X
|
XL Fleet Corp
XBER:XLF
|
US |
|
Cofidur SA
PAR:ALCOF
|
FR |
|
L
|
Linkers Industries Ltd
NASDAQ:LNKS
|
MY |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
US |
|
Wellnex Life Ltd
ASX:WNX
|
AU |
|
Computer Engineering & Consulting Ltd
TSE:9692
|
JP |
|
Archrock Inc
NYSE:AROC
|
US |
|
T
|
Thor Medical ASA
OSE:TRMED
|
NO |
|
H
|
Hanil Cement Co Ltd
KRX:300720
|
KR |
|
A
|
Atlas Global Brands Inc
CNSX:ATL
|
CA |
|
Graphic Packaging Holding Co
NYSE:GPK
|
US |
|
I
|
InFocus Group Holdings Ltd
ASX:IFG
|
AU |
Algernon Pharmaceuticals Inc
Algernon Pharmaceuticals Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).
Algernon Pharmaceuticals Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).
